ATE424417T1 - Diagnose und behandlung von hepatischen krankheiten - Google Patents
Diagnose und behandlung von hepatischen krankheitenInfo
- Publication number
- ATE424417T1 ATE424417T1 AT99922996T AT99922996T ATE424417T1 AT E424417 T1 ATE424417 T1 AT E424417T1 AT 99922996 T AT99922996 T AT 99922996T AT 99922996 T AT99922996 T AT 99922996T AT E424417 T1 ATE424417 T1 AT E424417T1
- Authority
- AT
- Austria
- Prior art keywords
- disorders
- madcam
- disorder
- compositions
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7840598A | 1998-05-13 | 1998-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE424417T1 true ATE424417T1 (de) | 2009-03-15 |
Family
ID=22143829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99922996T ATE424417T1 (de) | 1998-05-13 | 1999-05-12 | Diagnose und behandlung von hepatischen krankheiten |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1078006B1 (de) |
| JP (2) | JP4817494B2 (de) |
| AT (1) | ATE424417T1 (de) |
| AU (1) | AU3986699A (de) |
| CA (1) | CA2330000C (de) |
| DE (1) | DE69940503D1 (de) |
| DK (1) | DK1078006T3 (de) |
| ES (1) | ES2321994T3 (de) |
| IL (2) | IL139129A0 (de) |
| WO (1) | WO1999058573A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2257388T3 (es) * | 2001-11-05 | 2006-08-01 | Warner-Lambert Company Llc | Procedimientos y composiciones para la seleccion de integrinas. |
| US20070202097A1 (en) * | 2003-03-10 | 2007-08-30 | Krissansen Geoffrey W | Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof |
| MX370489B (es) * | 2004-01-09 | 2019-12-16 | Pfizer | Anticuerpos contra madcam. |
| ES2351057T3 (es) | 2005-07-08 | 2011-01-31 | Pfizer Limited | Anticuerpos contra madcam. |
| WO2012061074A1 (en) * | 2010-10-25 | 2012-05-10 | Elan Pharmaceuticals, Inc. | METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS |
| MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| WO2018016607A1 (ja) * | 2016-07-20 | 2018-01-25 | 国立大学法人京都大学 | IgG4関連疾患の検査方法 |
| AU2018300189B2 (en) | 2017-07-14 | 2025-05-15 | Pfizer, Inc. | Antibodies to MAdCAM |
| WO2019113280A1 (en) * | 2017-12-06 | 2019-06-13 | Emory University | Methods of managing hepatic steatosis |
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996024673A1 (en) * | 1995-02-10 | 1996-08-15 | Leukosite, Inc. | Mucosal vascular addressins and uses thereof |
| US6037324A (en) * | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
-
1999
- 1999-05-12 CA CA2330000A patent/CA2330000C/en not_active Expired - Lifetime
- 1999-05-12 JP JP2000548375A patent/JP4817494B2/ja not_active Expired - Lifetime
- 1999-05-12 IL IL13912999A patent/IL139129A0/xx active IP Right Grant
- 1999-05-12 AT AT99922996T patent/ATE424417T1/de not_active IP Right Cessation
- 1999-05-12 DE DE69940503T patent/DE69940503D1/de not_active Expired - Lifetime
- 1999-05-12 EP EP99922996A patent/EP1078006B1/de not_active Expired - Lifetime
- 1999-05-12 DK DK99922996T patent/DK1078006T3/da active
- 1999-05-12 WO PCT/US1999/010520 patent/WO1999058573A1/en not_active Ceased
- 1999-05-12 AU AU39866/99A patent/AU3986699A/en not_active Abandoned
- 1999-05-12 ES ES99922996T patent/ES2321994T3/es not_active Expired - Lifetime
-
2000
- 2000-10-18 IL IL139129A patent/IL139129A/en not_active IP Right Cessation
-
2010
- 2010-06-04 JP JP2010129284A patent/JP2010280659A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010280659A (ja) | 2010-12-16 |
| CA2330000A1 (en) | 1999-11-18 |
| IL139129A (en) | 2006-09-05 |
| AU3986699A (en) | 1999-11-29 |
| EP1078006B1 (de) | 2009-03-04 |
| ES2321994T3 (es) | 2009-06-15 |
| JP4817494B2 (ja) | 2011-11-16 |
| WO1999058573A1 (en) | 1999-11-18 |
| DK1078006T3 (da) | 2009-06-02 |
| IL139129A0 (en) | 2001-11-25 |
| DE69940503D1 (de) | 2009-04-16 |
| JP2002514660A (ja) | 2002-05-21 |
| EP1078006A1 (de) | 2001-02-28 |
| CA2330000C (en) | 2015-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Postma et al. | Long term effects of vincristine on the peripheral nervous system | |
| BR0011000A (pt) | Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico | |
| DE69940503D1 (de) | Diagnose und behandlung von hepatischen krankheiten | |
| EP0792156A4 (de) | Verfahren zur vorbeugung oder behandlung von vaskulären hämorragien und der alzheimerischen krankheit | |
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| BR0211062A (pt) | Combinações para o tratamento de distúrbios inflamatórios | |
| TR200002784T2 (tr) | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar | |
| EP2331095A4 (de) | Bestimmte kynurenin-3-monooxygenase-inhibitoren, pharmazeutische zusammensetzungen und anwendungsverfahren dafür | |
| ATE548354T1 (de) | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen | |
| NO993393D0 (no) | Fotokjemoterapeutiske blandinger | |
| BRPI0413326A (pt) | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel | |
| EA200000848A1 (ru) | Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта | |
| BR0206641A (pt) | Uso de compostos de azetidinona substituìda para o tratamento de sitosterolemia | |
| Costanza et al. | Therapy of malignant melanoma with an imidazole carboxamide and bis‐chloroethyl nitrosourea | |
| BRPI0413745A (pt) | horário mde dosagem para agentes anticancerìgenos erbb2 | |
| BR0313239A (pt) | Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças | |
| ATE497763T1 (de) | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen | |
| Attarian et al. | Magnetic stimulation using a triple‐stimulation technique in patients with multifocal neuropathy without conduction block | |
| EA200101212A1 (ru) | Замещенные полициклические арил- и гетероарилпиразиноны, которые могут использоваться при селективном ингибировании системы свертывания крови | |
| Claus et al. | Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam | |
| DE69426767D1 (de) | Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen. | |
| BRPI0416591A (pt) | métodos e reagentes para o tratamento de distúrbios inflamatórios | |
| DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| MA27690A1 (fr) | Composition pharmaceutique androgene et procede pour le traitement de la depression. | |
| EP1363528A4 (de) | Verfahren zur diagnose und behandlung von herzerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |